Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Curemark
Autism is currently a significant cause of disability in the pediatric population. CM-AT is based upon the observation that many children with autism do not digest protein. CM-AT is a proprietary enzyme that is designed as a powder taken three times a day. It is formulated to be released in the small intestine to enhance protein digestion thus increasing the availability of essential amino acids.
Age
9–12
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Meets the current Diagnostic and Statistical Manual for Mental Disorders (DSM-IV-TR) diagnostic criteria for autistic disorder (AD)
Ongoing 00102 Protocol required completion of 00101 Protocol
Now recruiting subjects directly into 00102 Protocol
You may not be if
Ongoing study required patients to be 3-8 years old weighing \< 11kg (24.2 lbs.), and achieving ages 9-12 years old weighing \< 22kg (48.4 lbs.).
Newly recruited subjects must be between ages 9 - 12 years old weighing \< 22kgs (48.4 lbs.)
Demonstrated previous allergy to porcine (pork) products
Previous history of severe head trauma or stroke, seizure within one year of entering study or uncontrolled systemic disease
Within 30 days of starting the study, certain supplementation, chelation or dietary restriction (a 30 day washout period would be required for inclusion)
Any use of psychotropic medications, stimulants, or SSRI's must be discontinued for 30 days prior to entrance
Clareo Health | A Trial of CM-AT in Children With Autism- Open Label Extension Study
